Cardio3 BioSciences reports positive data from C-Cure stem cell therapy clinical trial for heart failure
Cardio3 BioSciences, a leading Belgian biotechnology company specialising in regenerative therapies for the treatment of cardiovascular diseases, today announces positive safety data and preliminary efficacy results from its clinical trial of C-Cure(R), a breakthrough stem cell therapy for heart failure.
Leave a Response
You must be logged in to post a comment.
